Fremanezumab yields a greater reduction in the number of migraine days and headache days than placebo among children and adolescents with episodic migraine, according to a study published in the Jan. 15 issue of the New England Journal of Medicine.
Continue Reading
News Source: medicalxpress.com
Leave a Reply